Report Sections

See All Reports

  • HP:0002721: Immunodeficiency
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002721: Immunodeficiency

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (9)


    Name (Synonyms) Correlation
    drug2679 Omega 3/Nigella Sativa Oil/Anise seed capsule Wiki 0.45
    drug2682 Omega 3/Nigella Sativa Oil/Quinine pills Wiki 0.45
    drug976 Collection of blood samples in order to create a biocollection Wiki 0.45
    Name (Synonyms) Correlation
    drug2680 Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice Wiki 0.45
    drug2681 Omega 3/Nigella Sativa Oil/Indian Costus Wiki 0.45
    drug2678 Omega 3/Nigella Sativa Oil Wiki 0.45
    drug202 Active Comparator Wiki 0.45
    drug1549 Flow cytometric analysis Wiki 0.32
    drug3192 Questionnaire Wiki 0.08

    Correlated MeSH Terms (7)


    Name (Synonyms) Correlation
    D007153 Immunologic Deficiency Syndromes NIH 1.00
    D000077062 Burnout, Psychological NIH 0.11
    D004194 Disease NIH 0.07
    Name (Synonyms) Correlation
    D003141 Communicable Diseases NIH 0.03
    D007239 Infection NIH 0.02
    D045169 Severe Acute Respiratory Syndrome NIH 0.02
    D018352 Coronavirus Infections NIH 0.02

    Correlated HPO Terms (0)


    Name (Synonyms) Correlation

    Clinical Trials

    Navigate: Correlations   HPO

    There are 5 clinical trials


    1 Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function

    CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.

    NCT04354818
    Conditions
    1. HIV-1-infection
    2. Cancer
    3. Primary Immune Deficiency Disorder
    4. Immunosuppression Disorders
    5. COVID-19
    MeSH:Immunologic Deficiency Syndromes Disease
    HPO:Immunodeficiency

    Primary Outcomes

    Measure: percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died

    Time: Day 28

    Secondary Outcomes

    Measure: percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died

    Time: 3 months
    2 Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.

    A weekly questionnaire is sent to patients and parents of patients who are vulnerable for infections. Possible symptoms of COVID19 are asked for and use of healthcare services and testing for COVID19. Weekly reports are being send to the national institutions to update advice given to this group.

    NCT04382508
    Conditions
    1. Immune Suppression
    2. Immune Deficiency
    3. Infection
    4. COVID
    5. Children, Adult
    Interventions
    1. Other: Questionnaire
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Immunologic Deficiency Syndromes
    HPO:Immunodeficiency

    Primary Outcomes

    Description: To describe frequency of cough, fever, diarrhoea, shortness of breath, sore throat, blocked nose, red eyes, headache, joint pain, muscle pain, fatigue, chills, nausea, vomiting, diarrhoea over a year

    Measure: To describe COVID19 infection in children/adults who are vulnerable for infection in an outpatients setting

    Time: 1 year

    Secondary Outcomes

    Description: Patient/parent reported positive tests for COVID19

    Measure: Number of children/adults tested positive for COVID19

    Time: 1 year

    Description: Patient/parent reported admissions in hospital because of COVID19

    Measure: Number of children/adults admitted in hospital because of COVID19

    Time: 1 year

    Description: Patient/parent reported effect of COVID19 on daily activities

    Measure: To assess the impact of COVID19 infection on the daily activities of immunosuppressed adults and children

    Time: 1 year
    3 Multi-Center Prospective Cohort Study: Impact of Burnout on Cardiovascular and Immune Biomarkers Among Frontline Healthcare Professionals During Covid-19 Pandemic in Abu Dhabi Emirate

    The main objective of our project is to investigate the evolution of psychosocial, cardiovascular and immune markers in healthcare with different levels of exposure to the COVID-19 pandemic.

    NCT04422418
    Conditions
    1. Cardiovascular Risk Factor
    2. Burnout
    3. Immune Deficiency
    MeSH:Immunologic Deficiency Syndromes Burnout, Psychological
    HPO:Immunodeficiency

    Primary Outcomes

    Description: Burnout - through self-reported stress and burnout thoughts, beliefs, emotions, behavior related to Covid-19 using Maslach Burnout Inventory. Maslach Burnout Inventory - is a 22-item survey that covers 3 areas: Emotional Exhaustion (EE), Depersonalization (DP), and low sense of Personal Accomplishment (PA). Each subscale includes multiple questions with frequency rating choices of Never, A few times a year or less, Once a month or less, A few times a month, Once a week, A few times a week, or Every day.

    Measure: Change from Baseline Burnout at 2-3 months and 6 months

    Time: baseline, 2-3 months, 6 months

    Description: Data is collected through wearable monitoring technology. Cardiovascular risk through monitoring of heart rate variability (HRV) markers. Changes of heart rate variability (HRV) reflecting cardiac autonomic dysfunction are associated with greater risks for cardiac morbidity and mortality.

    Measure: Change from Baseline Cardiovascular Risk Cardiovascular Risk Through Heart Rate Variability Markers at 2-3 months and 6 months

    Time: baseline, 2-3 months, 6 months

    Description: Data is collected through wearable monitoring technology. Actigraphy data is collected in 1 min epochs using the zero-crossing modes.

    Measure: Change from Baseline Through Actigraphy at 2-3 months and 6 months

    Time: baseline, 2-3 months, 6 months

    Description: Data is collected through wearable monitoring technology. Sleep efficiency is defined as the proportion of the estimated sleep periods spent asleep. Sleep latency is the length of time taken to fall asleep, calculated as the time between 'lights off' to the first period of 3 min of consecutive epochs scored as sleep.

    Measure: Change from Baseline Through Sleep Quality at 2-3 months and 6 months

    Time: baseline, 2-3 months, 6 months

    Description: Cardiovascular risk through Fuster-BEWAT score. The Fuster-BEWAT score will be analyzed as a continuous variable with total score ranging from 0 to 15 points. Additionally, each component will be categorized as ideal (3) or nonideal (0 to 2), and participants will be classified as having poor, intermediate, or ideal cardiovascular health based on the total number of ideal components (0 to 1 = poor, 2 to 3 = intermediate, 4 to 5 = ideal) (Fernández-Alvira et al., 2017).

    Measure: Change from Baseline Cardiovascular Risk Through Fuster-BEWAT score at 2-3 months and 6 months

    Time: baseline, 2-3 months, 6 months

    Description: Classification of the immune function will be screened.

    Measure: Change from Baseline Immune Dysfunction at 2-3 months and 6 months

    Time: baseline, 2-3 months, 6 months

    Secondary Outcomes

    Description: Submaximal field test and maximal oxygen consumption (VO2, mL/kg/min).

    Measure: Change from Baseline Cardio-Respiratory Fitness at 2-3 months and 6 months

    Time: baseline, 2-3 months, 6 months
    4 Worldwide COVID-19 in Children and Adult Patients With Primary ImmunoDeficiencies (PID) Survey

    With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID). Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH & IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "COPID19". COPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password. Each documenting person will have access to his/her own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.

    NCT04459689
    Conditions
    1. Primary Immune Deficiency
    2. COVID
    MeSH:Immunologic Deficiency Syndromes
    HPO:Immunodeficiency

    Primary Outcomes

    Measure: Survival of patients with PID affected by COVID-19

    Time: Baseline

    Measure: Rate of admission to ICU of patients with PID affected by COVID-19

    Time: Baseline

    Measure: Rate of oxygen therapy of patients with PID affected by COVID-19

    Time: Baseline

    Secondary Outcomes

    Measure: Sequelae of patients with PID affected by COVID-19

    Time: Baseline
    5 Impact of Different Treatment Modalities on Immunity Against COVID-19

    The first version of this preprint article is registered on the 4th of May 2020 under the digital object identifier of:10.31219/osf.io/u56fc. COVID-19 infections virus spread worldwide and impact many countries with sever economical sequences. The effective antiviral medication or vaccination for the virus is unavailable until the present date and it takes months or years to discover the effective treatment or test the efficacy of the discovered treatment. Based on these facts, the human immune system against the virus may have an effective role to regulate the infection and reduce the mortality rate among the infected patients. This proposed research article aims to explore the available medication/ natural supplementation to boost the immunity system of the patients against COVID-19 infections and reduce the mortality rate among infected patients. Methods: a proposed clinical trial will be carried out to investigate the effect of the different treatment modalities on the human immune system against COVID-19 infection.

    NCT04553705
    Conditions
    1. Covid19
    2. Immunodeficiency
    Interventions
    1. Drug: Omega 3/Nigella Sativa Oil
    2. Drug: Omega 3/Nigella Sativa Oil/Indian Costus
    3. Drug: Omega 3/Nigella Sativa Oil/Quinine pills
    4. Drug: Omega 3/Nigella Sativa Oil/Anise seed capsule
    5. Drug: Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice
    6. Drug: Active Comparator
    MeSH:Immunologic Deficiency Syndromes
    HPO:Immunodeficiency

    Primary Outcomes

    Description: Time to Clinical recovery

    Measure: Clinical improvement

    Time: 30 Days

    Description: Percentage of patients returned to negative swaps of COVID-19

    Measure: Recovery rate from positive to negative swaps

    Time: 14 Days

    Description: Number of days for fever remission T=37.5°C

    Measure: Fever to normal temperature in days

    Time: 15 Days

    Description: Number of days to report lungs recovery in chest X ray or CT

    Measure: Remission of lung inflammation in CT or X-ray

    Time: 30 Days

    Description: Number of days for hospitalization

    Measure: Length of hospitalization

    Time: 10 Days

    Description: Change of (PCR levels) > 50% in comparison with PCR levels at the admission

    Measure: (PCR levels) polymerase chain reaction assay levels

    Time: 10 Days

    Description: P O2/Fi O2 which reflects patients' oxygen saturation

    Measure: Respiratory indexes

    Time: 10 Days

    Description: C-reactive protein milligrams per deciliter correlated with inflammation

    Measure: C-reactive protein mg/L

    Time: 25 Days

    Description: Serum Ferritin Nanograms per milliliter correlated with iron overload and illness severity

    Measure: Serum Ferritin ng/ml

    Time: 25 Days

    Description: Lactic acid dehydrogenase unit per litter correlated with illness severity

    Measure: Lactic acid dehydrogenase U/L

    Time: 25 Days

    Description: leukocytes in microliter correlated with mortality

    Measure: leukocytes count μl

    Time: 30 Days

    Description: Mg/dl correlated with lipid peroxidation that linked to oxidative stress

    Measure: Lipid profile [LDL, HDL, Total cholesterol ]

    Time: 14 Days

    Description: Evaluate the antioxidant response against the free radicals produced in COVID-19 infection measured by ELISA

    Measure: total plasma antioxidant capacity

    Time: 14 Days

    HPO Nodes


    HP:0002721: Immunodeficiency
    Genes 270
    DCLRE1C DKC1 NHEJ1 CDC42 AK2 DNAJC21 CD81 CD3E PGM3 CDC42 CD3G FOXN1 NFKB2 ANTXR2 SIK3 BCL10 TNFRSF13C STAT1 LIG4 ZBTB24 GP1BB USP8 IRAK4 IL2RG DNMT3B IFNGR1 SEC24C CHD7 CPLX1 RREB1 TNFRSF13C ZBTB24 LYST ARVCF STK4 RNF168 CYBB NFKB1 TINF2 TBX1 NSD2 IKZF1 LRBA IRF8 XRCC4 ACTB TYK2 HELLS FCN3 CDH23 CD28 MAN2B1 ATM WHCR MMUT ISG15 CR2 FCGR3A JMJD1C CD247 UFD1 IKBKB CTPS1 CREBBP UNG CTLA4 ICOS RAG1 CDCA7 BCL11B RMRP PRKCD GATA2 SPATA5 TICAM1 IL21R POLE CLCA4 STX1A RAG2 MALT1 TNFRSF4 RAB27A IRAK4 LRRC8A SHANK3 IRF2BP2 SDHC IGHM CD79A CFTR IGLL1 CD79B NHP2 EPG5 ACP5 MAN2B1 MTHFD1 BLNK LCK NFE2L2 AGL SLC46A1 LYST XIAP DKC1 IL12RB1 IL7R XIAP EPG5 SPATA5 POLE PIK3CD TTC7A NCF1 RTEL1 CD40 RNF168 IL2RB RAG2 PARN LMNB2 UROS WRAP53 CD19 NPM1 PTEN TNFRSF13C CORO1A PIK3R1 PRKDC CR2 SBDS EP300 PIK3CD CD40LG ICOS PKP1 KLLN RBCK1 ADA UNC119 SMARCAL1 ATRX USF3 BCR NCF2 CR2 RAG1 PRPS1 SDHD IL2RA IL2RG RAG2 PARN CHD1 AK2 TTC7A NOP10 CREBBP IL2RG PNP FOXN1 DOCK2 SH2D1A WIPF1 CD3D LETM1 CTC1 HYOU1 COMT TBX1 TBCE PGM3 RTEL1 IL7R MS4A1 NFKB2 ORAI1 CD19 EXTL3 TERC MYC MYD88 BUB1B CUL4B ADA2 IKBKG MBTPS2 TNFRSF13B RAG1 SP110 IL21 TLR3 CYBA XRCC4 LAMTOR2 TTC37 TERT PIK3CA SKIV2L IFNGR2 MEIS2 TFRC LAT DCLRE1C CD81 CARD9 UNC93B1 AP3D1 RTEL1 RAG1 NFKB1 SEC23B TNFRSF1B CTBP1 TRAF3 CTLA4 DNMT3B TGFB1 EFL1 FGFRL1 MAGT1 IL12B SRP54 TINF2 BTK FRAS1 GATA1 CARD11 RMRP WAS KNSTRN MAPK1 MS4A1 TERT PTPRC SDHB HBB TCF3 AKT1 ICOS DCTN4 USB1 DKC1 TNFRSF13B HIRA IKBKG TNFSF12 PIK3R1 ADA CD19 SKIV2L CCDC47 JAK3 IVNS1ABP LIG4 STAT1 CHD1 AICDA RAC2 ACD LAMTOR2 TNFSF12 STIM1 TBK1 CRKL IRF8 IRF7 STAT1
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0002721: Immunodeficiency
    Genes 270
    DCLRE1C DKC1 NHEJ1 CDC42 AK2 DNAJC21 CD81 CD3E PGM3 CDC42 CD3G FOXN1 NFKB2 ANTXR2 SIK3 BCL10 TNFRSF13C STAT1 LIG4 ZBTB24 GP1BB USP8 IRAK4 IL2RG DNMT3B IFNGR1 SEC24C CHD7 CPLX1 RREB1 TNFRSF13C ZBTB24 LYST ARVCF STK4 RNF168 CYBB NFKB1 TINF2 TBX1 NSD2 IKZF1 LRBA IRF8 XRCC4 ACTB TYK2 HELLS FCN3 CDH23 CD28 MAN2B1 ATM WHCR MMUT ISG15 CR2 FCGR3A JMJD1C CD247 UFD1 IKBKB CTPS1 CREBBP UNG CTLA4 ICOS RAG1 CDCA7 BCL11B RMRP PRKCD GATA2 SPATA5 TICAM1 IL21R POLE CLCA4 STX1A RAG2 MALT1 TNFRSF4 RAB27A IRAK4 LRRC8A SHANK3 IRF2BP2 SDHC IGHM CD79A CFTR IGLL1 CD79B NHP2 EPG5 ACP5 MAN2B1 MTHFD1 BLNK LCK NFE2L2 AGL SLC46A1 LYST XIAP DKC1 IL12RB1 IL7R XIAP EPG5 SPATA5 POLE PIK3CD TTC7A NCF1 RTEL1 CD40 RNF168 IL2RB RAG2 PARN LMNB2 UROS WRAP53 CD19 NPM1 PTEN TNFRSF13C CORO1A PIK3R1 PRKDC CR2 SBDS EP300 PIK3CD CD40LG ICOS PKP1 KLLN RBCK1 ADA UNC119 SMARCAL1 ATRX USF3 BCR NCF2 CR2 RAG1 PRPS1 SDHD IL2RA IL2RG RAG2 PARN CHD1 AK2 TTC7A NOP10 CREBBP IL2RG PNP FOXN1 DOCK2 SH2D1A WIPF1 CD3D LETM1 CTC1 HYOU1 COMT TBX1 TBCE PGM3 RTEL1 IL7R MS4A1 NFKB2 ORAI1 CD19 EXTL3 TERC MYC MYD88 BUB1B CUL4B ADA2 IKBKG MBTPS2 TNFRSF13B RAG1 SP110 IL21 TLR3 CYBA XRCC4 LAMTOR2 TTC37 TERT PIK3CA SKIV2L IFNGR2 MEIS2 TFRC LAT DCLRE1C CD81 CARD9 UNC93B1 AP3D1 RTEL1 RAG1 NFKB1 SEC23B TNFRSF1B CTBP1 TRAF3 CTLA4 DNMT3B TGFB1 EFL1 FGFRL1 MAGT1 IL12B SRP54 TINF2 BTK FRAS1 GATA1 CARD11 RMRP WAS KNSTRN MAPK1 MS4A1 TERT PTPRC SDHB HBB TCF3 AKT1 ICOS DCTN4 USB1 DKC1 TNFRSF13B HIRA IKBKG TNFSF12 PIK3R1 ADA CD19 SKIV2L CCDC47 JAK3 IVNS1ABP LIG4 STAT1 CHD1 AICDA RAC2 ACD LAMTOR2 TNFSF12 STIM1 TBK1 CRKL IRF8 IRF7 STAT1
    SNP 0

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook